MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$3,536K
Net cash provided by
(used in) financing...
$3,454K
(6055.17%↑ Y/Y)
Effect of exchange rate
on cash and cash...
$136K
(-66.83%↓ Y/Y)
Canceled cashflow
$82K
Net increase
(decrease) in cash and cash...
$2,939K
(266.14%↑ Y/Y)
Canceled cashflow
$651K
Principal payments on
short-term debt
$82K
(1.23%↑ Y/Y)
Accrued expenses and
other current...
$391K
(180.79%↑ Y/Y)
Accounts payable
$216K
(-78.95%↓ Y/Y)
Withholding tax payable
$63K
(-39.42%↓ Y/Y)
Stock-based compensation
$58K
(1.75%↑ Y/Y)
Operating lease
right-of-use asset
-$40K
(-108.93%↓ Y/Y)
Depreciation
$32K
(-11.11%↓ Y/Y)
Deferred consideration,
net of discount
$24K
(-56.36%↓ Y/Y)
Net cash used in
operating activities
-$649K
(67.79%↑ Y/Y)
Net cash used in
investing activities
-$2K
(98.11%↑ Y/Y)
Canceled cashflow
$824K
Accounts receivable, net
$650K
(200.93%↑ Y/Y)
Purchases of property and
equipment
$2K
(-98.11%↓ Y/Y)
Prepaid expenses and
other current assets
$364K
(-55.56%↓ Y/Y)
Net loss
-$330K
(73.41%↑ Y/Y)
Inventories, net
$81K
(-87.58%↓ Y/Y)
Operating lease
liabilities
-$40K
(-108.93%↓ Y/Y)
Deferred revenue
-$8K
(-130.77%↓ Y/Y)
Back
Back
Cash Flow
Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc. (SNOA)
source: myfinsight.com